Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:162
Name cancer
Definition A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT02484053 Phase I Rituximab Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders Completed
NCT03507491 Nab-paclitaxel Gemcitabine Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors Recruiting
NCT03536728 Oral AMXT 1501 Dicaprate in Combination With DFMO Recruiting
NCT03543358 Phase II Rovalpituzumab Tesirine A Long-Term Study of Rovalpituzumab Tesirine Completed
NCT03686124 TCR-engineered T Cells in Solid Tumors Recruiting
NCT03768063 FDA approved Atezolizumab A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) Recruiting
NCT03844048 Phase III Venetoclax An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Enrolling by invitation
NCT03899155 FDA approved Nivolumab Pan Tumor Nivolumab Rollover Study Recruiting
NCT03926143 Phase II Anetumab ravtansine A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies Enrolling by invitation
NCT04059588 A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin Recruiting